Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.
Precision oncology company making liquid-biopsy blood tests for cancer screening, treatment selection and recurrence monitoring.
Is paid per test: Medicare, insurers and patients pay for each blood sample analysed, while drug developers pay for tests used to select patients in trials. Guardant360, for advanced cancer, is the established earner; Shield, approved by the FDA in 2024 as a colorectal cancer screening test, is the newer line. The company is still loss-making.
Moat: narrow (data, IP / patents, scale). Large proprietary genomic/clinical dataset and a first-mover position in liquid biopsy testing.
Headquarters: Palo Alto, California, USA · Founded: 2012 · Employees: 2,506
Size Guardant Health (GH) is a United States Health Care company (Medical Specialties) with a market value of $19.6B, the 497th largest of 3,085 United States companies the cockpit tracks. Shares closed at $145.14 on 18 Nov 2026.
Performance Over six months the shares gained 26.2%, against +25.9% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 41.7% over the last twelve months (peer median +6.5%); the operating margin is -39.4% (peer median 17.4%).
Valuation It trades at 15.9× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 21).
Capital Return on invested capital runs 115.2 points below its cost of capital (12.8% WACC).
Credit Guardant Health has 2 bonds outstanding ($1.09B).
Short interest Short interest is 7.0% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.28B | $982M | $739M | $564M | $450M |
| Revenue growth | — | +33% | +31% | +25% | — |
| Gross profit | $834M | $633M | $449M | $337M | $292M |
| EBITDA | -$464M | -$397M | -$401M | -$520M | -$499M |
| Net income | -$485M | -$416M | -$436M | -$479M | -$655M |
| Free cash flow | -$220M | -$233M | -$275M | -$345M | -$387M |
| Capital expenditure | $58.7M | $48.3M | $35.1M | $20.5M | $77.5M |
| Total debt | $1.69B | $1.71B | $1.34B | $1.35B | $1.37B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Guardant Health GH | $19.6B | +26% | +42% | -39% | 15.9× | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | 14.1× | n/a |
| GRAIL GRAL | $4.59B | +67% | +17% | -332% | 23.3× | n/a |
| Tempus AI TEM | $11.6B | +39% | +37% | -18% | 8.2× | n/a |
| Caris Life Sciences CAI | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% |
| Personalis PSNL | $1.62B | +88% | +17% | -157% | 18.2× | n/a |
| Adaptive Biotechnologies ADPT | $4.61B | +104% | +18% | -16% | 15.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.7% | +5.7% | 2nd lowest of 21 |
| 6-month return | +26.2% | +25.9% | 10th highest of 21 |
| Distance from 52-week high | -24.0% | -9.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +41.7% | +6.5% | 2nd highest of 21 |
| Operating margin | -39.4% | 17.4% | lowest of 21 |
| EV / Sales | 15.9× | 6.0× | 2nd most expensive of 21 |
| ROIC minus cost of capital | -115.2 pp | +2.2 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | 15.9× | n/a | n/a |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 3.1× | 7.4% | +3.2% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 4.9× | 6.0% | +6.7% |
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 6.3× | 25.6% | +8.7% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 6.6× | 16.2% | +12.8% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 6.5× | 26.4% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 4.6× | -2.1% | +8.3% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 3.1× | 8.8% | +13.0% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 7.9× | 33.4% | +9.2% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 4.3× | 14.0% | +13.8% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 6.0× | n/a | n/a |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 19.6× | n/a | n/a |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 8.2× | 25.8% | +7.4% |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 12.4× | 53.2% | +33.5% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 1.7× | 13.4% | -0.7% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 2.0× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 7.8× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 2.5× | 11.1% | +5.6% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 6.0× | 19.6% | +19.3% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 7.2× | 27.2% | +6.0% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 2.6× | 8.6% | +5.5% |
Guardant Health has 2 bonds outstanding with $1.09B face value.